Moderna-Merck Melanoma Vaccine Hits Phase 3 Goal, Igniting mRNA Cancer Race

Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its primary endpoint in a pivotal Phase 3 trial, showing statistically significant improvement in keeping melanoma from recurring or spreading compared to immunotherapy alone. The study, called INTerpath 001, enrolled over 1,100 high-risk patients whose tumors had been surgically removed, and tested the vaccine in combination with Merck's blockbuster drug Keytruda.

Zoom Out

This breakthrough lands at a pivotal...